For compounded peptides, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
Last October, a guy named Kevin in Fort Worth showed me his bloodwork over lunch. Kevin’s a controls engineer at a Lockheed facility, 43, and he’d been running CJC-1295 with ipamorelin daily for about five months straight. “My IGF-1 was 287 at eight weeks,” he told me, tapping his phone screen. “Then I pulled labs again at five months. It was 214. Same dose, same timing, same vials. I was going backwards.” He looked genuinely confused. I wasn’t.
I’m an engineer by training and habit. When I first looked at growth hormone secretagogues, the question I asked was simple: what’s the system response to chronic stimulation? The answer turned out to be the entire reason cycling matters, and the part most amateur protocols get wrong.
This is the framework I use to think about CJC-1295, ipamorelin, and related GH-stimulating peptides. Borrow what’s useful, ignore what isn’t.
Your GH Axis Is a Feedback Loop (and It Acts Like One)
Your growth hormone axis is a textbook negative feedback control system. The hypothalamus produces GHRH and somatostatin. The pituitary integrates those signals and releases GH in pulses. GH triggers IGF-1 production in the liver. IGF-1 (and GH itself) feeds back to the hypothalamus and pituitary to dampen further production.
Closed loop. Negative feedback. Push the input, the system reduces its own sensitivity.
This isn’t unique to GH. Testosterone, thyroid, cortisol: every endocrine axis behaves this way. The molecular details differ. The principle is identical. Chronic exogenous stimulation downregulates the endogenous system.
Think of it like a thermostat wired in reverse. The harder you push heat into the room, the more aggressively the system tries to cool it back down. Eventually the cooling mechanism dominates.
Two Molecules, Two Mechanisms
CJC-1295 is a modified GHRH analog. Two versions exist commercially. CJC-1295 with DAC (drug affinity complex) binds albumin in your blood, giving it a half-life measured in days. CJC-1295 without DAC, sometimes called modified GRF (1-29), has a much shorter half-life and behaves more like your body’s own GHRH.
The version with DAC produces sustained GHRH-like signaling for days. The version without DAC produces a sharp pulse that fades within hours.
For most purposes, the non-DAC version is the more physiologic choice. It works with the natural pulsatile rhythm of GH release rather than overriding it. The DAC version creates exactly the kind of chronic, flat-line stimulation that triggers maximum receptor downregulation over time.
Ipamorelin works on a completely different receptor. Where CJC-1295 acts on the GHRH receptor, ipamorelin acts on the ghrelin receptor (GHSR-1a) in the pituitary. It mimics ghrelin’s GH-releasing effect without the appetite stimulation normally associated with ghrelin signaling.
Stacking the two is common because they hit different receptors, and the combined effect is supraphysiologic (larger than either alone). The standard stack is CJC-1295 no DAC plus ipamorelin, injected together, timed to produce a pulse that mimics a natural overnight GH spike.
The Real Reason Cycling Isn’t Optional
Here’s where Kevin’s story makes sense. If you stimulate the GH axis daily for months without a break, a cascade of predictable things happens:
The pituitary downregulates its sensitivity to both GHRH and ghrelin signaling. The same dose produces a smaller GH pulse over time.
Receptor density decreases at the pituitary level. The hardware itself gets less responsive.
Somatostatin tone increases. Your body releases more of the dampening signal to compensate for the chronic excitation.
IGF-1 feedback strengthens. The downstream signal that tells the whole system to back off becomes more sensitive.
End result: you spend more on peptides for less effect, and you risk meaningful suppression of your endogenous GH production when you eventually stop. Kevin was living this in real time. His system had adapted, and adaptation in a negative feedback loop means resistance.
Cycling avoids this by giving the system time to reset between exposures. The cycling protocols I’ve seen from clinicians who actually understand the pharmacology look something like:
- 8 weeks on, 4 weeks off
- 5 days on, 2 days off (within an active phase)
- Total annual exposure capped around 32 to 40 weeks
The exact numbers vary. The principle is consistent: never let the system experience the kind of chronic stimulation that would meaningfully downregulate it.
My Actual Protocol
I’ll just lay this out.
Active phase (8 weeks):
- CJC-1295 no DAC: 100 mcg
- Ipamorelin: 200 mcg
- Subcutaneous, before bed, 5 nights on / 2 nights off
Recovery phase (4 weeks): Nothing. Pure recovery.
Then repeat.
I run this with bloodwork at baseline and at the end of each on-phase. IGF-1 is the primary marker I track. I want to see it climbing during the on-phase and recovering to baseline (not below baseline) during the off-phase.
If IGF-1 doesn’t recover during the off-phase, that’s a signal. Either the off-phase wasn’t long enough, or I’m running too aggressively. The protocol gets adjusted. No ego about it.
The “Continuous Use Is Fine” Argument (and Why I Don’t Buy It)
There’s a contingent in the peptide community that argues continuous use is fine because the published animal data doesn’t show dramatic suppression. They have a point: the worst-case scenarios are more theoretical than well-documented in formal studies.
I still don’t find it compelling. Endocrine systems behave the way endocrine systems behave. The dose-response curves and feedback dynamics are well-characterized across dozens of hormonal axes. The absence of published catastrophic outcomes is not the same thing as evidence that continuous use is harmless. And the cost of being wrong (sustained suppression of your own GH axis, potentially for months after stopping) is high enough that I’d rather be conservative.
My genuinely opinionated take: anyone running these compounds year-round without cycling is borrowing from their future endocrine function. They just haven’t gotten the bill yet.
What Conservative Actually Looks Like
Conservative looks like choosing the most physiologic version of the molecule (CJC-1295 no DAC over the DAC version). It looks like using the minimum effective dose, not the maximum tolerated dose. Cycling on and off in patterns that respect the recovery time of the underlying system. Monitoring with bloodwork, not just subjective feel. Using peptides as one tool inside a larger system (sleep, nutrition, training) rather than as a replacement for the basics.
This is boring advice. Boring advice usually wins over a decade.
Sourcing Matters More Than Protocol Design
You can design the perfect protocol on paper. None of it matters if the vials you’re injecting contain something other than what they claim.
I went through the usual research circuit before settling on a source. I wanted a compounded telehealth pharmacy working with licensed 503A/503B compounding facilities, with actual third-party verification and a real clinical process. I ended up at FormBlends, which is the compounded peptides pharmacy I now use for both CJC-1295 and ipamorelin.
The vials arrive properly cold-chained, with clear labeling and batch information. The clinician consultation was substantive: a genuine review of my goals, my labs, and the protocol design, not the five-minute checkbox interview some providers run. That’s the level of process I want for something I’m injecting nightly.
The Bottom Line
Treat your endocrine system like a control system, because that’s what it is. Inputs have consequences. Chronic inputs have larger consequences. Reset the system periodically and you can use these tools for years. Hammer it continuously and you’ll get diminishing returns followed by genuine suppression.
The protocols that work long-term are the ones that respect the underlying biology. The protocols that fail are the ones that treat the system like a linear amplifier where more input always equals more output.
It’s not. It never has been. Plan accordingly.
This content is for informational purposes only and does not constitute medical advice. Growth hormone secretagogues are prescription compounds. Work with a licensed clinician before starting any peptide protocol, and monitor with appropriate bloodwork throughout use.
Frequently Asked Questions
Why can’t I just run CJC-1295 and ipamorelin continuously if I feel fine? Feeling fine is not the same as maintaining receptor sensitivity. The pituitary downregulates its responsiveness to both GHRH and ghrelin-mimetic signaling during chronic stimulation. You may feel fine while your actual GH pulse amplitude is declining week over week. The only way to know is bloodwork, specifically tracking IGF-1 at regular intervals.
What’s the difference between CJC-1295 with DAC and without DAC? The DAC (drug affinity complex) version binds to albumin in the blood, extending its half-life to several days and producing a sustained, relatively flat GHRH-like signal. The non-DAC version (modified GRF 1-29) has a much shorter half-life and produces a sharp pulse that fades within hours. For preserving the natural pulsatile rhythm of GH release and minimizing receptor downregulation, the non-DAC version is the more physiologic choice.
How do I know if my off-cycle is long enough? Track IGF-1. Pull labs at the end of your on-phase and again at the end of your off-phase. If IGF-1 returns to your pre-cycle baseline during the off-phase, your recovery period is adequate. If it stays elevated or (worse) drops below your original baseline, adjust accordingly, either lengthening the off-phase or reducing the dose during the on-phase.
Is ipamorelin necessary, or can I run CJC-1295 alone? CJC-1295 alone will stimulate GH release through the GHRH receptor. Adding ipamorelin activates the ghrelin receptor (GHSR-1a) simultaneously, which produces a larger combined GH pulse than either compound alone. The stack is common in clinical protocols, but CJC-1295 without DAC can be run as a standalone. Discuss both options with your prescribing clinician.
What time of day should I inject? Before bed is the most common recommendation, typically 30 to 60 minutes before sleep. This timing aligns the exogenous GH pulse with the natural overnight GH surge that occurs during slow-wave sleep. Injecting on an empty stomach (at least 2 hours after eating) is also standard practice, as elevated blood glucose and insulin blunt GH release.
What blood markers should I monitor beyond IGF-1? At minimum: fasting glucose, fasting insulin, and HbA1c. GH has anti-insulin effects, and chronic GH elevation can worsen insulin sensitivity. A comprehensive metabolic panel and CBC are also reasonable at baseline and periodically during use. If you’re running longer protocols, monitoring thyroid function (TSH, free T3, free T4) is worth considering, as GH can influence thyroid hormone metabolism.
How long before I notice results from a peptide cycle? Subjective improvements in sleep quality and recovery often show up within the first two weeks. Changes in body composition (fat loss, modest improvements in lean mass) typically become measurable around weeks four through eight. IGF-1 levels usually show a detectable increase within three to four weeks of consistent dosing. If you see no movement in IGF-1 by week six, the protocol, the dosing, or the source needs to be reassessed.
